Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 40 to 80

Using Sildenafil to Improve Exercise Capacity in Mild COPD

Official title: The Effect of Oral Sildenafil on Exercise Capacity, Dyspnea and Cardiopulmonary Function in Chronic Obstructive Pulmonary Disease (COPD)

Run by University of Alberta · NCT05061368 · Data updated 2026-11-12

This study is testing if the medication Sildenafil can help people with mild COPD exercise better and breathe easier.

Quick facts

PhasePhase 2
Study typeInterventional
Ages40 Years to 80 Years
SexAll
Enrollment160 (estimated)
SponsorUniversity of Alberta
Academic / other
Locations1 site (Edmonton, Alberta)
StatusRecruiting
StartedMarch 1, 2022
Main results expectedMay 2027
Study endsMay 2027
Registry record updatedNovember 5, 2026
Trial IDNCT05061368 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are individuals diagnosed with mild COPD who meet specific pulmonary function criteria.

Probably not a fit

Patients with moderate to severe COPD or those with pre-existing cardiac conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of oral Sildenafil on exercise capacity, dyspnea, and cardiopulmonary function in patients with mild Chronic Obstructive Pulmonary Disease (COPD). The study aims to understand how pulmonary vascular dysfunction contributes to exercise intolerance in these patients. Participants will be given either Sildenafil or a placebo, and their responses will be measured through various pulmonary function tests and exercise assessments. The trial seeks to clarify the mechanisms behind exertional dyspnea in mild COPD and evaluate the potential therapeutic benefits of Sildenafil.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment options for patients with mild COPD, enhancing their exercise capacity and quality of life.

How similar studies have gone: Previous studies have shown promising results using similar approaches to address pulmonary vascular dysfunction in COPD, indicating potential for success in this trial.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Participants will have COPD as defined as:

1. Post bronchodilator Forced Expiratory Volume in one second (FEV1) to Forced Vital Capacity (FVC) ratio (FEV1/FVC) below the lower limit of normal
2. FEV1 \>30% of predicted (lower limit of GOLD severe COPD classification)

COPD Free Controls will have:

1. No diagnosis of COPD
2. Post bronchodilator Forced Expiratory Volume in one second (FEV1) to Forced Vital Capacity (FVC) ratio (FEV1/FVC) above the lower limit of normal
3. FEV1 \>80% of predicted

Exclusion Criteria:

1. Absolute contraindication to exercise testing or an orthopedic condition that may limit exercise testing.
2. Pre-existing cardiac conditions (heart failure, congenital heart defect, valvular disease) that may limit exercise testing
3. A diagnosis of pulmonary hypertension preceding COPD
4. Current phosphodiesterase type-5 inhibitor, nitrate, opioid, azole antifungal, macrolide antibiotic, protease inhibitor, alpha blocker, riociguat, mifepristone or rifamycin use.
5. Pregnancy or lactation.
6. Women of childbearing potential must be willing to use an acceptable method of contraception to avoid pregnancy throughout the study. Acceptable methods of contraception include tubal ligation, oral contraceptive, barrier methods (intra-uterine device, diaphragm, female condom, male condom). Abstinence is an acceptable form of contraception, only insofar as patients agree to use another acceptable method of birth control, preferably a barrier method, if they become sexually active.
7. Postmenopausal female participants must be amenorrheic for ≥12 months.

Where it's running

  • Clinical Physiology Laboratory
    Edmonton, Alberta, Canada
    Recruiting

Study contacts

  • Principal investigator: Michael K Stickland, Ph.D. — University of Alberta
  • Study coordinator: Desi Fuhr, MSc
  • Email: fuhr@ualberta.ca
  • Phone: 7804921121

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.